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Editor 
Biochemical and Biophysical Research Communications 
 
RE:  




We would be very pleased if you would consider our manuscript for publication in Biochemical and 
Biophysical Research Communications. Below is a brief summary of the background and purpose 
of our study. 
 
In this report, we demonstrated that mPGES-2 can be cleaved by BACE-1, which leads to 
neuroinflammation in the brain. In addition to APP, novel substrates of BACE-1 have been 
identified. Furthermore, we demonstrated that amyloid beta treatment augmented protein levels of 
mPGES-2, which synthesizes PGE2. In addition, we revealed that a sequence of amino acids at the 
N-terminal of mPGES-2 is cleaved by BACE-1, which results in an activated form of mPGES-2. We 
also observed the translocation of mPGES-2, BACE-1, and COX-2 to the perinuclear space. 
Multiple lines of evidence, ranging from molecular and cellular to epidemiological data, have 
highlighted the importance of inflammation in the pathogenesis of Alzheimer’s disease (AD). Our 
results imply that amyloid beta can evoke neuroinflammation by BACE-1-mediated cleavage of 
mPGES-2, which can aggravate the pathogenesis of AD. 
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We previously indicated that amyloid beta (Abeta) augments protein levels of beta-site amyloid 
precursor protein cleaving enzyme-1 (BACE-1) through oxidative stress. In this study, we revealed 
that BACE-1 is involved in the cleavage of membrane-bound prostaglandin E2 synthase-2 
(mPGES-2) in its N-terminal portion, which, in turn, enhanced the generation of prostaglandin E2 
(PGE2). PGE2 results in increased Abeta production, initiating a cell-injuring cycle. Using rat 
primary cortical neurons, a 48 h treatment with Abeta 1-42 (5 M) resulted in the enhanced 
extracellular PGE2 levels up to about 1 ng/mL, which was attenuated by treatment with a BACE-1 
inhibitor (200 nM). A synthetic peptide sequence of 20 amino acids that included the cleavage site of 
mPGES-2 (HTARWHL RAQDLHERS AAQLSLSS) was cleaved by recombinant BACE-1, 
confirmed using reverse-phase high-performance liquid chromatography. Cleaved or activated 
mPGES-2 augments the generation of PGE2. In addition, mPGES-2 was determined to be 
colocalized with BACE-1 and cyclooxygenase-2 in the perinuclear region in cells after exposure to 
Abeta. Exposure of neurons to PGE2 led to cell death, and Abeta production was enhanced by PGE2 
(1 ng/mL, 48 h). Collectively, these results suggest that Abeta might cause neuroinflammation that 
aggravates Alzheimer’s disease pathogenesis.  
 
Keywords: Abeta; Alzheimer’s disease; BACE-1; COX-2; mPGES-2; PGE2. 
 
Abbreviations used: Abeta, amyloid beta; AD, Alzheimer’s disease; APP, amyloid precursor 
protein; BACE-1, beta-site APP cleaving enzyme-1; COX, cyclooxygenase; EP, E prostanoid;  
cPGES, cytosolic prostaglandin E2 synthase-2; HPLC, high performance liquid chromatography; 
mPGES-1, microsomal prostaglandin E2 synthase-1; mPGES-2, microsomal prostaglandin E2 
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It has been suggested that inflammation is involved in the pathogenesis of Alzheimer’s disease (AD) 
[1]. Specifically, the accumulation of microglia around senile plaques and elevated levels of 
inflammatory cytokines, chemokines, proteases, and reactive oxygen species have been observed in 
the brains of AD patients. In and around the senile plaques and neurofibrillary tangles, microglial 
cells are activated, and the number of reactive astrocytes is increased. Collectively, these data have 
led to the hypothesis that brain inflammation is a cause of neuronal injury in AD. 
Prostaglandins (PGs) are chemical mediators and potent inducers of inflammation. Cyclooxygenases 
(COXs) catalyze the conversion of free arachidonic acid to the endoperoxide intermediate PGG2, 
which is then reduced by peroxidase activity to PGH2. PGH2 is metabolized rapidly, resulting in 
different end products depending on the relative abundance of synthases in different cell types. 
Examples of these end products include PGI2, thromboxane A2, PGD2, PGE2, and PGF2 alpha.  
PGE2 is also catalytically converted from PGH2 by prostaglandin E synthase (PGES). It has been 
reported that levels of PGE2 are increased in the cerebrospinal fluid (CSF) of AD [2], and the highest 
levels are observed in the very early stages of AD. These levels then decline with progressive 
cognitive impairment [3]. In vitro experiments have revealed that PGE2 release is enhanced by 
amyloid beta (Abeta) [4], a major constituent of senile plaques found in AD brains. Furthermore, 
Abeta induced COX-2 activity may subsequently catalyze the production of PGE2 [4].  
The four receptor subtypes of PGE2 are E prostanoid (EP) receptors1-4. Deletion of the EP2 receptor 
in aged amyloid precursor protein (APP) Swe-PS1ΔE9 mice, which were used as a transgenic mouse 
model of AD, results in lower levels of Abeta peptides and less accumulation of amyloid deposits [5]. 
Conversely, the metabolism of Abeta might be influenced by PGE2. Therefore, PGE2 may play a key 
role in the early stages of AD pathogenesis, especially in Abeta-related events. 
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PGES is a membrane-associated protein involved in eicosanoid and glutathione metabolism. There 
are three types of PGES: cPGES, mPGES-1 and mPGES-2. Cytosolic glutathione (GSH)-dependent 
prostaglandin (PG) E2 synthase (cPGES) is a terminal enzyme of COX-mediated PGE2 biosynthetic 
pathway. Functional coupling between COX-1 and cPGES was reported to be important for the 
synthesis of PGE2 [6]. Microsomal PGES-1 (mPGES-1) is a perinuclear protein that is markedly 
induced by proinflammatory stimuli, and is functionally coupled with COX-2. 
Microsomal PGES-2 (mPGES-2), another PGES, is a Golgi membrane-associated protein. The 
proteolytic removal of its N-terminal hydrophobic domain leads to the formation of a mature 
cytosolic enzyme [7,8]. In addition, over-expression of full-length mPGES-2 was found to be 
spontaneously converted to the N-terminal truncated form. This truncated version of the enzyme is 
similar in size to the deletion mutant mPGES-2, which lacks 87 amino acids at the N-terminal [8]. 
The cleavage of mPGES-2 regulates its enzymatic activities.  
Beta-site APP-cleaving enzyme 1 (BACE-1), also known as beta-amyloid-converting enzyme 1, has 
been identified as a membrane-bound aspartic protease, chiefly located in the Golgi apparatus. 
Amyloid precursor protein (APP) is first cleaved by BACE-1 and subsequently by gamma-secretase 
to generate beta-amyloid. Inhibitors of BACE-1 are proposed therapeutics for AD. Recent reports 
indicate that novel substrates are cleaved by BACE-1 [9,10,11]. Proteolytic cleavage can control the 
fate of enzymes, and thus BACE-1 might contribute to the regulation of enzymes. 
It has been suggested that BACE-1 is one of the stress-responsive proteins. In this study, we 
investigated the function of BACE-1 in Abeta-induced inflammation, and revealed that mPGES-2 





Materials and methods  
 
Reagents. The drugs and materials used in these experiments were obtained from the following 
sources: human amyloid beta peptide 1-42 (Abeta 1-42) (Peptide Institute, Osaka, Japan); 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) (Nacalai tesque, Kyoto, Japan); primary 
neuron culture materials (Invitrogen, CA, USA); 4’, 6-diamidino-2-phenylindole (DAPI) and fura-2 
fluorescence reagent (Dojindo. Tokyo, Japan); MTX-LDH Kit (Kyokuto, Tokyo, Japan); 
anti-BACE-1 (Millipore, MA, USA); anti-mPGES-1, anti-mPGES-2, anti-cPGES, and anti-COX-2 
antibodies (Cayman Chemical, MI, USA); and anti-Lamin A (Abcam, MA, USA). 
 
Neuron cultures. The use of experimental animals in this study was conducted in accordance with the 
ethical guidelines of the Kyoto University Animal Experimentation Committee. Primary neuron 
cultures were obtained from a fetal rat cerebral cortex (18 days gestation) following previously 
described procedures. Briefly, cells that dissociated from the cerebral cortex of fetal rats were plated 





. Cultures were incubated in neurobasal medium with 2% B27 supplement without 
antioxidants, 25 μM Glutamate, and 0.5 mM L-glutamine. After 4 days in vitro, the medium was 
replaced by glutamate free medium (neurobasal medium supplemented 2% B27, and 0.5 mM 
L-glutamine). Cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2. Only 
mature cultures (10-11 days in vitro) were used.  
 
Astrocyte cultures. Primary astrocyte cultures were obtained from postnatal day 1 (P1) rat cortex. 
Briefly, dissociated cells were seeded into 75-cm
2
 tissue culture flasks and incubated for 20-24 days 
in Eagle’s minimum essential medium (EMEM) supplemented with 10% FBS and 50 µg/ml 
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kanamycin at 37ºC in a 5% CO2/95% air humidified incubator. Flasks were shaken at 400 rpm (10 
min, 37ºC) and then at 220 rpm (15 hr, 37ºC). Astrocyte cultures were detached with solution 
minimal essential medium (SMEM) containing 0.25 µg/ml trypsin and were cultured in Dulbecco’s 
modified Eagle’s Medium (DMEM) (10% FBS and 50 µg/ml kanamycin) at 2.5×104 cells/cm2. 
 
Microglial culture. Microglial cells were obtained from the cortex of postnatal day 0–1 rats. For the 
induction of differentiation, the enriched microglial cells were cultured in DMEM supplemented 
with 10% FBS and 10 ng/ml macrophage colony stimulating factor (M-CSF; R&D Systems, 
Minneapolis, MN) for three days (days 1–3), in DMEM containing 70% FBS and M-CSF for two 
days (days 4 and 5), and then in serum-free DMEM in the presence of 20 ng/ml bFGF (PeproTech, 
London, UK) for four days (days 6–9). 
 
Measurement of Cell Viability. Neuronal cell viability in culture was estimated by a MTT reduction 
assay. Briefly, treated cells (in a 48-well plate) were incubated at 37 °C for 30 minutes with media 
that included MTT (0.1 mg/mL in neurobasal media, 200 μL). After incubation, the MTT solution 
was replaced with 2-propanol (200 μL), followed by 1 min of shaking. Next, this solution was 
transferred to a 96-well plate, with each well containing 180 μL of solution. Absorption was 
measured at 570 nm by a microplate spectrophotometer (Model 680 plate reader BioRad, USA). The 
cell viability was expressed as the percentage of surviving cells and compared to the 100% survival 
observed in control cultures.  
 
Preparation of cell extracts and western blotting. After each treatment, cells were lysed in a buffer 
consisting of 20 mM Tris/HCl, pH 7.0, 2 mM EGTA, 25 mM 2-glycerophosphate, 1% Triton X-100 
and a protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). Then, the cell extracts were 
centrifuged at 16,200 g for 20 minutes at 4 °C. The supernatants were used as the cell extracts for 
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immunoblot analysis. The protein concentration of each sample was determined using a micro BCA 
Protein Assay kit (Piers, CA, USA). Protein samples in sodium dodecyl sulfate buffer were loaded 
onto sodium dodecyl sulfate-polyacrylamide gels. After electrophoresis, proteins were 
electrotransferred to a polyvinylidene difluoride membrane (Millipore, CA, USA). Membranes were 
incubated with antibodies in 20 mM Tris/HCl, pH 7.6, 135 mM NaCl, 0.1% Tween 20 containing 5% 
nonfat dry milk. Subsequently, membranes were incubated with horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse antibodies. Immunoreactive bands were detected by enhanced 
chemiluminescence (GE Healthcare, CA, USA). Immunoblots were visualized by a ChemiDoc CCD 
camera detection system (Bio-Rad, CA, USA), and quantitatively analyzed by Quantity-One 
software (Bio-Rad, CA, USA).  
 
Evaluation of the cleavage of mPGES-2 peptide by RP-HPLC. A synthetic 20-amino acid peptide 
component of mPGES-2 that included the cleavage site (HTARWHL RAQDLHERS AAQLSLSS; 
indicated in Figure 4) was prepared according to the sequence indicated in EMBL Nucleotide 
Sequence Database (Accession number AK024100). Cleavage of the peptide was analyzed by 
reverse-phase high-performance liquid chromatography (RP-HPLC) using a C-18, YMC column. 
Peptides were separated using a stepwise gradient of acetonitrile. The peptide was dissolved in 
DMSO and diluted with assay buffer. Subsequently, 30 μL of peptide and 1 μL of recombinant 
human BACE-1 were mixed.   
 
Immunocytochemistry. For the immunofluorescence staining, cells were fixed with 0.1 M phosphate 
buffer containing 4% paraformaldehyde for 15 min. Fixed cells were rinsed with PBS three times 
and blocked with 5% goat serum in PBS with 0.005% saponin for 30 min and incubated overnight at 
4 °C with anti-BACE-1 (1:200), anti-mPGES-2 (1:250), anti-COX-2 (1:300), or anti-Lamin A 
(1:500) antibodies diluted in PBS containing 1% goat serum and 0.005% saponin. The next day, the 
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cells were washed three times and then incubated for 1 h at room temperature with Cy3-AffiniPure 
goat anti-mouse IgG (1:1600) or Cy2-AffiniPure goat anti-mouse IgG (1:1600). Cultures were 
washed with PBS, treated with FluorSave Reagent (Calbiochem, Germany), covered, and examined 
under an Olympus photomicroscope equipped for epifluorescence. Digital images were obtained 
with a CCD camera. 
 
PGE2 and Abeta enzyme-linked immunosorbent assay (ELISA). After cultures were treated in 
neurobasal medium containing 2% B27 supplement for 24 h at 37 °C, debris was removed by 
centrifugation, and the media were then applied to ELISA plates. The culture media were analyzed 
for prostaglandin production using a monoclonal PGE2 enzyme-linked immunosorbent assay 
(ELISA) (Cayman Chemicals, MI, USA), or for Abeta 1-40 or Abeta 1-42 using Human/Rat Abeta 
1-40 or Abeta 1-42 ELISA Kit (Wako Pure Chemical, Tokyo, Japan), following the manufacturer s’ 
instructions.  
 
Statistical Analysis. Statistically significant differences between groups were determined by an 
analysis of variance followed by a Dunnett or Newman-Keuls post-hoc analysis. The level of 






Abeta induces the production of PGE2 
To investigate Abeta-induced inflammation, we measured extracellular PGE2 levels induced by 
Abeta, using an ELISA. Administration of Abeta 1-42 for 48 h significantly increased PGE2 levels in 
the media of neuronal culture (Fig. 1A). Simultaneous administration of BACE-1 inhibitor IV (200 
nM) significantly suppressed Abeta 1-42-induced PGE2 up-regulation (5 M, 48 h). These results 
suggest BACE-1 is involved in the production of PGE2 induced by Abeta. In contrast, exposure of 
neuronal cells to lipopolysaccharide (LPS) also significantly increased PGE2. Secreted levels of 
PGE2 were more prominent than PGE2 levels resulting from Abeta stimulation, and BACE-1 
inhibitor IV did not suppress LPS-induced PGE2 up-regulation (Fig. S1). 
Previously, we demonstrated that exposure of Abeta 1-42 to neuronal cultures increased BACE-1 
protein levels [12]. As the Abeta peptide might form a cross-linked complex directly with COX-2, 
we investigated the effect of indomethacin, a COX inhibitor, upon Abeta-induced BACE-1 
up-regulation (Fig. 1B). Administration of Abeta 1-42 for 48 h significantly increased BACE-1 
expression levels. Simultaneous administration of indomethacin (10 M) significantly suppressed 
Abeta 1-42-induced BACE-1 up-regulation (5 M, 48 h) in a concentration dependent manner. 
Ibuprofen also attenuated the BACE-1 up-regulation induced by Abeta (data not shown). These 
results suggest COX activation may be involved in the increase of BACE-1 levels. 
 
Abeta enhances the protein levels of BACE-1, COX-2 and PGE2 synthase 
We next investigated the cell type responsible for the production of PGE2. cPGES, mPGES-1, and 
mPGES-2 are responsible for the synthesis of PGE2. Therefore, the protein levels of these enzymes 
were analyzed by western blotting (Fig. 2A).  
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Exposure to Abeta increased the protein level of mPGES-2 significantly in pure neuron and 
astrocytic cultures. On the other hand, Abeta did not affect cPGES levels in any cell culture. In all 
cultures, mPGES-1 was not detected. These data suggest that mPGES-2 may be an inducible enzyme 
that is responsive to Abeta. 
COX-2 activity can also be induced by various stimuli or stress. It has been reported that expression 
of COX correlates with levels of Abeta. Therefore, we evaluated the expression level of COX-2 
using pure neuronal, astrocyte, and microglia cultured cells. As shown in Figure 2A, COX-2 levels 
were enhanced by Abeta treatment in all cell cultures.   
Although BACE-1 was not detectable in the microglia culture, BACE-1 expression was determined 
to be enhanced in the pure neuronal culture and in the astrocyte culture.  
 
N-terminal 20-residue peptide of mPGES-2 was cleaved by BACE-1 
It has been shown that 87-residues of the N-terminus of mPGES-2 can be cleaved in the cytoplasm, 
resulting in an active form of mPEGS-2. This fragmentation leads to the release of mPGES-2 from 
the Golgi membrane and allows mPGES-2 to migrate to other intracellular organs. In order to clarify 
the involvement of the cleavage of the N-terminal sequence by BACE-1, we prepared a 20-residue 
peptide including the 87
th
 amino acid sequence of mPGES-2 (Fig. 2B). After the in vitro reaction of 
this synthetic peptide (20AA) with recombinant BACE-1, the peptide wacs separated by reverse 
HPLC using a C18 column.  
HPLC analysis revealed a single peak when the 20AA peptide was administered alone. Following the 
reaction of 20AA with BACE-1, three peaks were found. Two of the peaks might represent the 
cleaved peptides, while the other is the original peak. These results suggest thatBACE-1 can cleave 
mPGES-2. 
 
PGE2-induced neuronal death 
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Simultaneous treatment with BACE-1 inhibitor IV, which reduced Abeta-induced neuronal death, 
also reduced Abeta-induced PGE2 production. We therefore investigated whether PGE2 is toxic to 
neurons using MTT assay. As a result, administration of synthetic PGE2 induced neuronal death in a 
concentration dependent manner (Fig. 3A). From these data, we concluded that Abeta administration 
leads to the augmentation of PGE2 mediated via BACE-1, which in turn induces, at least in part, 
neuronal death.  
 
Extracellular Abeta secretion was increased by PGE2-related inflammation 
Previously, it was indicated that PGE2 caused Abeta secretion [13]. We also confirmed that Abeta 
1-40 or 1-42 levels were augmented by PGE2 treatment. Synthetic PGE2 treatment significantly 
increased the Abeta 1-40 and 1-42 levels in a concentration-dependent manner (Fig. 3B, C).  
 
Colocalization of mPGES-2 and BACE-1 or COX-2 was induced by Abeta 
To clarify whether mPGES-2 colocalizes with BACE-1 or COX-2, mixed culture cells were 
immunostained and analyzed by photomicrographs. mPGES-2 colocalized with BACE-1 in cells 
after exposure to Abeta (Fig. 4A).  
While COX-2 did not colocalize with mPGES-2 in a resting state (Fig. 4B), administration of Abeta 
led to the colocalization of mPGES-2 and COX-2. Simultaneous administration of the BACE-1 
inhibitor attenuated the Abeta-induced colocalization of mPGES-2 and COX-2. Exposure to Abeta 
induced the assemblies of mPGES-2, BACE-1 and COX-2 in the perinuclear region (Fig. 4B).  
COX-2 is mainly located in the nuclear membrane. Lamin-A, a nuclear membrane marker, 
colocalized with mPGES-2 after exposure to Abeta (Fig. 4C). Simultaneous administration of the 
BACE-1 inhibitor attenuated this phenomenon.  
These data suggest that Abeta induces the association of BACE-1 and mPGES-2, which causes the 









BACE-1 is an aspartic protease, and cleavage of APP has been investigated for the elucidation of AD 
pathogenesis. In addition to APP, novel BACE-1 substrates have recently been identified [9,10,11]. 
BACE-1 might be activated by various stress stimuli, and it might therefore cleave stress-reactive 
peptides.  
mPGES-2 is synthesized in the Golgi membrane, and it then undergoes a proteolytic event where its 
N-terminal hydrophobic domain is removed. This truncated enzyme is subsequently released into the 
cytoplasm. Abeta stimulation induced the translocation of mPGE2 to perinuclear region where 
BACE-1 also assembles. Therefore, it is possible that BACE-1 cleaves mPGES-2 in the perinuclear 
region. Further supporting this hypothesis is the fact that mPGES-2 possesses one hydrophobic 
region, and it is therefore possible that its enzyme structure is similar to that of APP, another known 
BACE-1 substrate. 
The 20-amino acid synthetic mPGES-2 peptide was determined by EMBL Nucleotide Sequence 
Database (Accession number AK024100) to contain the N-terminal 87
th
 amino acid sequence of 
PGE2. The full-length protein of mPGES-2 is spontaneously converted to an N-terminal truncated 
form, which is similar in size to the reported deletion mutant of mPGES-2 that lacks the N-terminal 
87
th
 amino acid sequence [8]. We hypothesized that since either mature or truncated mPGES-2 has 
been reported to exhibit bioactivity, that cleavage product of PGE2 mediated by BACE-1 would be 
bioactive, we therefore prepared this peptide.  
Full length mPGES-2 is associated with the Golgi membrane, and it is dispersed in the cytoplasm 
after removal of the N-terminal region [8]. However, our data suggest that Abeta-stimulated cells 
exhibit assemblies of mPGES-2 and BACE-1 around the nucleus. IL-1beta-treated fibroblasts show 
overlapping expression of COX-2 and mPGES-2 primarily in the perinuclear region [14]. mPGES-2 
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is constitutively synthesized and is not regulated by IL-1beta. Some stimuli might cause the 
translocation of mPGES-2 without up-regulation in protein synthesis.  
It has been reported that both COX-1 and COX-2 mediate mPGES-2-promoted PGE2 production, 
with COX-2 being slightly preferred [8]. In our data, Abeta induced the translocation of COX-2 from 
the nucleus to the perinuclear region, where mPGES-2 was also found. Treatment with a 
BACE-inhibitor attenuated this phenomenon, indicating the involvement of BACE-1 in this process. 
BACE-1-induced cleavage of mPGES-2 would activate the enzyme promoting its translocation to the 
perinuclear region where it could couple with COX-2 and contribute to the production of PGE2.  
In addition to the increases in the processing and translocation of mPGES-2, its protein levels were 
also augmented. The induction of PGE synthase mRNA levels by treatment of cells with Abeta has 
previously been reported [15]. However, the precise mechanism is not known, and it is not clear why 
mPGES-2 mRNA was up-regulated.  
Previously we have reported that Abeta treatment induces increases in BACE-1 protein levels [12]. 
This change may be due to increased BACE-1 transcription by Abeta [16]. BACE-1 may in turn 
cleave APP to produce more Abeta. In this study, we demonstrated that Abeta treatment leads to the 
production of PGE2, which up-regulates Abeta.  
It has been reported that PGE2 stimulates the production of Abeta [13]. Specifically, PGE2 induces 
internalization of presenilin 1 (PS1), followed by the activation of gamma-secretase [17]. Abeta 
simultaneously up-regulates BACE-1, which causes ectodomain shedding of APP. APP is 
subsequently cleaved to produce Abeta, which propagates the vicious cycle of AD pathogenesis  
Our data demonstrated that PGE2 treatment induced neurotoxicity. Abeta-induced PGE2 levels or 
PGE2-induced Abeta levels were not sufficient in quantity to result in neurotoxicity. Previously, we 
have shown that Abeta-induced neurotoxicity is attenuated by treatment with BACE-1 inhibitors [12]. 





In conclusion, Abeta causes BACE-1 up-regulation, which cleaves mPGES-2, which is subsequently 
translocated to the perinuclear region where it synthesizes PGE2 collaboratively with COX-2. As a 
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Legends to figures 
 
Fig. 1. Abeta induced production of PGE2 and enhanced the protein level of BACE-1 via 
COX-2. (A) Neuronal cultures were exposed to Abeta 1-42 for 48 h, and media were analyzed using 
a monoclonal PGE2 enzyme-linked immunosorbent assay (ELISA). Abeta treatment significantly 
increased PGE2 levels in a concentration-dependent manner. Simultaneous administration of 
BACE-1 inhibitor IV (200 nM) significantly suppressed Abeta 1-42 (5 M, 48 h)-induced PGE2 
up-regulation. Data are expressed as Mean  SEM, n = 4. *p < 0.05, **p < 0.01, compared with 
control (CTL; vehicle alone), 
##
p < 0.01, compared with Abeta 1-42 5 M. (B) Administration of 
Abeta 1-42 for 48 h significantly increased BACE-1 expression levels. Simultaneous administration 
of indomethacin (10 M) significantly suppressed Abeta 1-42 (5 M, 48 h)-induced BACE-1 
up-regulation. 
  
Fig. 2. Abeta enhanced the protein levels of PGE2 synthase, and BACE-1 was involved in the 
activation of mPGES-2. (A) After 48 h-exposure to Abeta 1-42 (5 M), cells were lysed and 
prepared for the immunoblot analysis. Representative data of BACE-1, COX-2 and PGE2 synthase 
levels. BACE-1 and mPGES-2 levels were increased by Abeta treatment in neuronal and astrocytic 
cell cultures. In microglial cells BACE-1 was not detected, and mPGES-2 levels were constant. 
COX-2 protein levels were increased in neuronal, astrocytic and microglial cell cultures. Levels of 
cPGES were not changed by Abeta treatment. mPGES-1 was not detected in our cultures. P.C.; 
positive control prepared from the recombinant protein. (B) Quantitative analysis of mPGES-2 
protein levels. **p < 0.01, compared with control (vehicle alone; CTL), N.S., not significant. (C, D) 
N-terminal 20-residue peptide of mPGES-2 was cleaved by BACE-1. (C) Schematic structures of 
mPGES-2 and selected 20 amino acids. (D) Cleavage of the peptide was analyzed by reverse-phase 
20 
 
high-performance liquid chromatography (RP-HPLC) using a C-18, YMC column. The 20-residue 
peptide was indicated as a single peak (top chromatogram), which was reduced by recombinant 
human BACE-1 (middle chromatogram). The bottom chromatogram represents the overlay of the 
20-reisude peptide chromatogram and the BACE-1 reduced peptide chromatogram. 
 
Fig. 3. PGE2 induced neuronal death and extracellular Abeta secretion. (A) Neuronal cultures 
were exposed to PGE2 for 48 h. Viabilities were evaluated by MTT assay. Synthetic PGE2 induced 
neuronal death in a concentration-dependent manner. Data are expressed as Mean  SEM, n = 4 ** p 
< 0.01, compared with control (vehicle alone; CTL). 
(B), (C) Abeta 1-40 or Abeta 1-42 in the media was quantified using ELISA assays. Synthetic PGE2 
treatment significantly increased the Abeta 1-40 and 1-42 levels in a concentration dependent manner. 
Data are expressed as Mean  SEM, 5 of control. N = 4. *p < 0.05, **p < 0.01, compared with 
control (vehicle alone; CTL)  
 
Fig. 4. Abeta induced colocalization of BACE-1, mPGES-2 and COX-2. (A) Exposure to Abeta 
led to the colocalization of mPGES-2 and BACE-1. (B) Exposure to Abeta led to the colocalization 
of mPGES-2 and COX-2. Simultaneous administration of BACE-1 inhibitor (BACEI) attenuated the 
Abeta-induced colocalization of mPGES-2 and COX-2. (C) Lamin-A, a nuclear membrane marker, 
was colocalized with mPGES-2 after exposure to Abeta. Simultaneous administration of BACE-1 
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